Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding Inc (NQ: MORF )

29.84 +0.35 (+1.17%)
Streaming Delayed Price Updated: 10:25 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Morphic Holding Inc

< Previous 1 2 Next >
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition- 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
Via Investor Brand Network
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action
Via Investor Brand Network
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic Announces Proposed Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis 
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at SVB Leerink Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
First patient dosed in global study of oral α4β7 integrin inhibitor 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
From Morphic Therapeutic
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.